Current status of antitumor therapy with monoclonal antibodies - PubMed (original) (raw)
Affiliations
- PMID: 3079479
Review
Current status of antitumor therapy with monoclonal antibodies
D A Scheinberg et al. Oncology (Williston Park). 1987 May.
Abstract
The potential power of monoclonal antibodies arises from their ability to recognize single antigenic determinants in a complex mixture of molecules or cells. The possibilities for cancer therapy are apparent. But to what extent has the potential been realized? What problems have arisen in clinical trials?
Similar articles
- [Use of monoclonal antibodies in the immunotherapy of neoplasms].
Robak T. Robak T. Przegl Lek. 1989;46(4):420-6. Przegl Lek. 1989. PMID: 2672121 Review. Polish. No abstract available. - The use of monoclonal antibody immunoconjugates in cancer therapy.
Pietersz GA, Krauer K, McKenzie IF. Pietersz GA, et al. Adv Exp Med Biol. 1994;353:169-79. doi: 10.1007/978-1-4615-2443-4_16. Adv Exp Med Biol. 1994. PMID: 7985535 Review. No abstract available. - Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B, Siegel SE, Kaiser HE. Bodey B, et al. Anticancer Res. 1996 Mar-Apr;16(2):661-74. Anticancer Res. 1996. PMID: 8687112 Review. - Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins.
Shapira S, Lisiansky V, Arber N, Kraus S. Shapira S, et al. Expert Opin Investig Drugs. 2010 Apr;19 Suppl 1:S67-77. doi: 10.1517/13543781003737668. Expert Opin Investig Drugs. 2010. PMID: 20374033 Review. - Improving the efficacy of antibody-based cancer therapies.
Carter P. Carter P. Nat Rev Cancer. 2001 Nov;1(2):118-29. doi: 10.1038/35101072. Nat Rev Cancer. 2001. PMID: 11905803 Review.
Cited by
- Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB. LoBuglio AF, et al. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4220-4. doi: 10.1073/pnas.86.11.4220. Proc Natl Acad Sci U S A. 1989. PMID: 2726771 Free PMC article. Clinical Trial. - Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells.
Primus FJ, Pendurthi TK, Hutzell P, Kashmiri S, Slavin DC, Callahan R, Schlom J. Primus FJ, et al. Cancer Immunol Immunother. 1990;31(6):349-57. doi: 10.1007/BF01741406. Cancer Immunol Immunother. 1990. PMID: 2386980 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources